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Lamivudine population pharmacokinetics were investigated by using nonlinear mixed-effect modelling
(NONMEM) analysis of data from 394 human immunodeficiency virus (HIV)-infected patients treated with
lamivudine (150 to 300 mg every 12 h) in two large, phase III clinical efficacy-safety trials, NUCA3001 and
NUCA3002. Analyses of 1,477 serum lamivudine concentration determinations showed that population esti-
mates for lamivudine oral clearance (CL/F; 25.1 liters/h) and volume of distribution (V/F; 128 liters) were
similar to values previously reported for HIV-infected patients in phase I pharmacokinetic studies. Lamivudine
CL/F was significantly influenced by the covariates creatinine clearance and weight and not affected by age,
Centers for Disease Control and Prevention (CDC) classification, CD41 cell count, HIV type 1 (HIV-1) RNA
PCR, or gender and race when CL/F was corrected for differences in patient weight. The population estimate
for lamivudine V/F was not significantly influenced by the covariates gender, race, age, weight, renal function,
HIV-1 RNA PCR, or CDC classification and CD41 cell count when creatinine clearance was included with CL/F
in the model. Lamivudine disposition was significantly influenced by renal function. However, as only three
patients had an estimated creatinine clearance of <60 ml/min, dosage adjustments for patients with impaired
renal function should not be determined based on the population parameters derived in this analysis.
The reverse transcriptase inhibitor lamivudine, administered
in combination with zidovudine and a protease inhibitor, has
proven effective in improving surrogate markers of human
immunodeficiency virus (HIV) disease and delaying disease
progression and death in the treatment of HIV-infected pa-
tients (7, 8). Although the pharmacokinetics of lamivudine
have been assessed in several phase I and phase I/II dose-
ranging studies, each of which involved small numbers of HIV
type 1 (HIV-1)-infected patients (4 to 12 patients per study) (1,
10, 11, 13, 14, 16, 17, 19, 21), no study to date has evaluated
lamivudine population pharmacokinetics. Population pharma-
cokinetic studies are important because they address the de-
mographic or disease-related factors in the targeted treatment
population that may significantly alter the pharmacokinetics of
a particular therapeutic agent (18, 20). Nonlinear mixed-effect
modeling (NONMEM), as implemented in the NONMEM
program (3), has been applied previously to estimate the
population pharmacokinetic parameter means, interindividual
variances, and intraindividual (residual) variances of the re-
verse transcriptase inhibitors zidovudine and didanosine (6,
15). The primary objectives for the present study were to (i)
define the population pharmacokinetics of lamivudine from
sparse sampling obtained during two large, phase III clinical
trials, NUCA3001 and NUCA3002, and (ii) identify the influ-
ence of gender, race, renal function, weight, age, and surrogate
markers of HIV disease on lamivudine pharmacokinetics.
(The results of this population pharmacokinetic analysis
were previously presented in part [13a, 22].)
The study designs for NUCA3001 and NUCA3002 have
been described previously (2, 5). NUCA3001 evaluated the
clinical efficacy and safety of 150 mg of lamivudine given twice
daily with 200 mg of zidovudine three times daily (n 5 92), 300
mg of lamivudine given twice daily (n 5 87), 300 mg of lami-
vudine given twice daily with 200 mg of zidovudine given three
times daily (n 5 94), and 200 mg of zidovudine given three
times daily (n 5 93) for 52 weeks to 366 antiretroviral therapy-
naive patients (#4 weeks of previous zidovudine treatment) at
26 sites (5). NUCA3002 evaluated the clinical efficacy and
safety of 150 mg of lamivudine given twice daily with 200 mg of
zidovudine given three times daily (n 5 84), 300 mg of lami-
vudine given twice daily with 200 mg of zidovudine given three
times daily (n 5 84), and 0.75 mg of zalcitabine given three
times daily with 200 mg of zidovudine given three times daily
(n 5 86) for 52 weeks to 254 zidovudine-experienced patients
($6 months of previous zidovudine treatment) at 21 sites (2).
In both clinical trials, lamivudine doses were given twice daily,
as two 75-mg tablets (for the 150-mg regimen) or as one
300-mg tablet of Epivir (Glaxo Wellcome Inc., Research Tri-
angle Park, N.C.), at approximately 8 am and 4 pm.
At the week 2 or 4 clinic visit, blood samples were collected
for pharmacokinetic evaluations. Selected centers participated
in intensive pharmacokinetic evaluations (six blood samples
per visit) in which an indwelling catheter, maintained via saline
flush, was placed in a forearm vein for blood sampling. A 2-ml
blood sample was drawn and discarded, a 10-ml predose sam-
ple was drawn, and then 10-ml samples were drawn at 0.5, 1,
2.5, 3.5, and 8 h postdose. Following collection of the 8-h
sample, the second study drug dose was administered and the
regular dosing schedule was resumed. The remaining sites par-
ticipated in limited pharmacokinetic evaluations (two blood
samples per visit) at the week 2 and 4 clinic visits. Patients were
instructed to refrain from taking their morning dose of the
study drug until they arrived at the clinic and a 10-ml sample of
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blood was collected. If a patient had taken the last dose of the
study drug during the 6 h preceding collection of the first
sample, a second blood sample was drawn at least 1 h after the
first and the usual dosing schedule was resumed. If the last
study drug dose was taken more than 6 h before collection of
the first blood sample, the study drug was to be administered
immediately and a second blood sample was to be taken at
least 1 h later. Study drug administration was to be restarted
with the evening dose on the day of the clinic visit.
Blood samples were evaluated for serum lamivudine con-
centrations, which were determined by methods previously re-
ported (9). For NUCA3001, the serum assay for lamivudine
was linear over the calibration range of 3 to 5,000 ng/ml (r $
0.996) (9). The interday percent coefficient of variation (%CV)
for the assay was 14.7% at 6 ng/ml, 3.6% at 150 ng/ml, and
0.9% at 3,500 ng/ml. For NUCA3002, the serum assay for
lamivudine was linear over the calibration range of 3 to 5,000
ng/ml (r $ 0.997). The interday %CV for the assay was 15.2%
at 6 ng/ml and 4.8% at 3,500 ng/ml.
Data from NUCA3001 and NUCA3002 were combined for
pharmacostatistical analysis. Patients were included in this
analysis if they had an adequate dosing history (including time
of dose administration prior to the time when the serum drug
concentration was determined) and measurable serum lamivu-
dine concentrations (above the limit of quantitation of the
assay). Creatinine clearance was chosen as the most convenient
clinically appropriate measure of renal function, since it is
typically used for dose adjustments. Gender, age, weight, se-
rum creatinine, CD41 cell count, HIV-1 RNA PCR, and Cen-
ters for Disease Control and Prevention (CDC) classification
were generally obtained during the patient’s second visit after
entry into the study. If no value was reported for that date, the
next available value for the patient was used, if obtainable.
Lamivudine pharmacokinetic data were fitted to a one-com-
partment open model with first-order elimination (ADVAN2
TRANS2). A proportional-error model was used to describe
the interindividual variability in pharmacokinetic parameters
and residual variability in the model. Population pharmacoki-
netics and Bayesian parameter estimates were based on the
intense and limited sampling described above. NONMEM
techniques (software package NONMEM, version 4, level 2)
(3) were used to develop a pharmacostatistical model to de-
scribe lamivudine population pharmacokinetics after oral ad-
ministration and to define the influence of specific covariates
(gender, race, age, weight, renal function, and surrogate mark-
ers of HIV disease) on lamivudine disposition. The first-order
conditional estimation process with an interaction option was
employed in NONMEM analyses. Serum drug concentration
and time data were used to estimate oral lamivudine clearance
(CL/F), apparent volume of distribution (V/F), and absorption
rate constant (ka). A covariance step was executed in each run
to obtain the standard errors of the estimate, covariance ma-
trix, and correlation matrix. To assess model fit, scatterplots
were created which included predicted versus observed con-
centrations (PRED versus CONC 5 DV with unity line), re-
sidual and weighted residuals versus time (RES WRES versus
TIME), and residual and weighted residuals versus observed
and predicted concentrations (RES WRES versus CONC
PRED).
The model-building process employed a two-step approach
to determine the inclusion of covariates. Initially, a basic (base)
pharmacokinetic model was fitted to the data. Individual
Bayesian parameter estimates were obtained from this model.
Scatterplots and summary plots of individual Bayesian esti-
mates and covariates were used to screen for appropriate co-
variates to include in the pharmacostatistical model. Likely
candidate covariates were then added to the pharmacostatis-
tical model. The influence of each covariate on clearance and
volume was examined separately and compared to the base
model (no covariates). Covariates that significantly improved
the objective function were further examined in combinations
as follows: weight and race on CL/F, weight and gender on
CL/F, race and creatinine clearance on CL/F, creatinine clear-
ance and CL/F on CD41 cell count and V/F, and creatinine
clearance and CL/F on CDC classification and V/F.
The criteria for accepting a NONMEM model estimation
included the following: (i) convergence of the objective func-
tion (“successful termination” statement by the NONMEM
program), (ii) standard error of estimates not larger than half
of the estimates, (iii) number of significant digits .3, (iv)
termination of the covariance step without warning messages,
and (v) correlations between model parameters of ,0.95. The
likelihood ratio was used to assess whether the difference in
objective function between the base model and the full (more
complex) model statistically improved the fit of the model to
the data. A decrease in objective function (D) of .7.88 (P 5
0.005, based on the likelihood ratio, which is approximately x2
distributed), compared to the base model, was considered sig-
nificant. A decrease in D of .10.60 was considered significant
when the model contained two additional parameters. A su-
perior model also was expected to reduce the intersubject
variance terms and/or the residual error term.
Statistical analyses (SAS version 6.10) were also used to
evaluate potential variables that may influence lamivudine
pharmacokinetic parameters obtained from the base model.
Stepwise regression analyses were performed to determine re-
lationships between continuous variables (weight, creatinine
clearance [4], age, number of CD41 cells per cubic millimeter,
and number of HIV-1 RNA PCR copies per milliliter) and
lamivudine CL/F and V/F. Analysis of variance was used to
assess the influence of categorical data (gender, race, CDC
classification, CD41 cell count category, and HIV-1 RNA PCR
category) on lamivudine CL/F and V/F. Statistically significant
(P , 0.05) interactions were examined in the NONMEM
model for evaluation of goodness of fit.
Of 1,721 measurable lamivudine concentrations available,
1,477 with adequate dosing and sample time documentation
were included in the lamivudine population pharmacokinetic
analysis. Of the 441 patients who received lamivudine in the
two clinical studies, 394 were included in the analysis (245 from
NUCA3001 and 149 from NUCA3002). The patient popula-
tion was predominantly (87%) male and had a mean age of
35.7 years, a mean weight of 74.2 kg, a mean calculated creat-
inine clearance of 97.4 ml/min, a mean CD41 cell count of
306/mm3, and a mean HIV-1 RNA PCR number of 43,723
copies/ml (Table 1).
In stepwise regression analyses performed between CL/F
and V/F against age, weight, and creatinine clearance, the fol-
lowing relationships achieved statistical significance: CL/F ver-
sus creatinine clearance (P 5 0.0001; r2 5 0.0761), CL/F versus
weight (P 5 0.0265; r2 5 0.0881), and V/F versus weight (P 5
0.0001; r2 5 0.5006). In stepwise regression analyses per-
formed between CL/F and V/F against gender, race, CDC
classification, CD41 cell count, and HIV-1 RNA PCR, the
following categorical analyses achieved statistical significance:
CL/F versus race (P 5 0.0307; not significant when CL/F was
normalized for weight [P 5 0.1270]), weight-normalized V/F
versus race (P 5 0.0017), CL/F versus gender (P 5 0.0221; not
significant when CL/F was normalized for weight [P 5
0.8538]), V/F and gender (P 5 0.0451), and weight-normalized
CL/F and HIV-1 RNA PCR (P 5 0.0139).
NONMEM results were consistent with stepwise regression
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and analysis of variance results. No differences were observed
with the following models when compared with the base mod-
el: V/F versus gender, V/F versus weight, V/F versus race, V/F
versus creatinine clearance, V/F and CL/F versus age, V/F and
CL/F versus CD41 cell count, CL/F versus CDC classification,
and V/F and CL/F versus HIV-1 RNA PCR. Weight signifi-
cantly influenced the population estimate of lamivudine CL/F
(D 5 224.818). Less remarkable differences in objective func-
tion were found when gender (D 5 28.945) and race (D 5
29.171) were included in the model as covariates of CL/F
when compared to CL/F normalized for weight. No differences
were observed in weight-normalized lamivudine CL/F between
Caucasians and members of other races (D 5 20.879). Dif-
ferences in CL/F due to gender were observed. However,
these were redundant when weight was included in the mod-
el (weight-normalized lamivudine CL/F between men and
women, D 5 20.112). CDC classification significantly influ-
enced the population estimate for V/F (D 5 216.828), but
CD41 cell count, a more sensitive measure of HIV disease,
was less remarkable (D 5 28.441). When creatinine clearance
was combined with CDC classification or CD41 cell count as
covariates of CL/F and V/F, respectively, no significant differ-
ences were observed (D 5 28.27 and D 5 26.513 compared to
the creatinine clearance model, respectively).
Depending on the model, population pharmacokinetic pa-
rameter estimates varied between 4.07 and 26.7 liters/h for
CL/F, 255 and 150 liters for V/F, and 3.80 and 5.48 h21 for ka.
The final (superior) model estimated CL/F at 25.1 liters/h, V/F
at 128 liters, and ka at 4.65 h21 (Table 2). As for residual error,
ε was 0.163 (40.4%), with a standard error (ε) of 0.012. An
adequate correlation was observed in the final model between
predicted and observed serum lamivudine concentrations
(Fig. 1), weighted residuals and predicted concentrations, and
weighted residuals and time profiles. Lamivudine disposition is
best described by a two-compartment model. Attempts to fit a
two-compartment model with first-order absorption either
failed to converge or failed to converge to a meaningful result,
and such a model was not identifiable by using the available
data. All possible combinations of additive- or proportional-
error models for interpatient variability on pharmacokinetic
parameters and error model on concentration were examined.
The only compartmental pharmacokinetic model to success-
fully fit the data was a one-compartment model with first-order
absorption. It is known that lamivudine absorption is rapid,
with a time to maximum drug concentration in serum of 1 to
1.5 h. Blood samples were generally collected 1 h or later after
dosing. Thus, there were insufficient data to describe the ab-
sorption process.
Renal function as a covariate greatly improved the fit of the
TABLE 1. Demographics of patients who participated in
NUCA3001 and NUCA3002 and had adequate
dosing and sample time documentation
Parameter NUCA3001 NUCA3002 Combined
No. of evaluable patients 245 149 394
No. (%) of:
Males 213 (87) 129 (87) 342 (87)
Females 32 (13) 20 (13) 52 (13)
Age (yr)
Mean 34.9 36.9 35.7
Range 19–61 22–64 19–64
Wt (kg)
Mean 75.3 72.4 74.2
Range 47.2–138.5 37.2–115.5 37.2–138.5
No. (%) that were:
Caucasian 152 (62) 92 (62) 244 (62)
Black 38 (16) 20 (13) 58 (15)
Hispanic 52 (21) 35 (24) 87 (22)
Other 3 (1) 2 (1) 5 (1)
Serum creatinine (mg/dl)
Mean 1.11 1.09 1.1
Range 0.6–1.6 0.6–1.7 0.6–1.7
No. (%) CDC category:
A 170 (69) 73 (49) 243 (62)
B 65 (27) 60 (40) 125 (32)
C 10 (4) 16 (11) 26 (6)
No. (%) with CD41 cell
count (cells/mm3) of:
,100 0 (0) 12 (8) 12 (3)
101–200 17 (7) 50 (34) 67 (17)
201–500 196 (80) 87 (58) 283 (72)
.500 32 (13) 0 (0) 32 (8)
No. (%) with PCR count
(copies/ml)a of:
,50,000 244 (99.6) 77 (52) 309 (81)
.50,000 1 (0.4) 72 (48) 73 (19)
No. (%) receiving:
Lamivudine alone 82 (33) 0 (0) 82 (21)
Lamivudine 1 zidovudine 163 (67) 149 (100) 312 (79)
a For PCR category only, n was 237 in NUCA3001, 145 in NUCA3002, and 382
for the combined studies.










CL/F (liters/h),d u1 25.1 23.8–26.4 35.2 0.683 0.124 0.0183
V/F (liters),e u2 128 117–139 31.1 5.72 0.0965 0.0278
ka (h21),f u3 4.65 2.18–7.12 1.26
u4 0.468 0.233–0.703 0.120
a CI, confidence interval.
b u, fixed effects.
c h, random effects between individuals.
d If male, CL/F 5 [u1 z (140 2 age/serum creatinine z 100)u4 EXPh2] z weight/
70; if female, CL/F 5 {u1 z [(140 2 age/serum creatinine z 100) z 0.85]u4 z Exph2} z
weight/70.
e V/F 5 u2 z EXPh2.
f ka 5 u3. Error model: F z EXP(ε1).
FIG. 1. Correlation between predicted and observed serum lamivudine con-
centrations in the final model.
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model to the data. A significant difference in objective function
was found when creatinine clearance was included in the
model as a covariate of CL/F (D 5 239.182). The model was
defined as follows: CL/F (liters per hour) 5 4.07 z (creatinine
clearance/100) 1 21 z (weight/70), %CV 5 38.7%, V/F 5 161
liters (%CV 5 36.7%), and ka 5 6.39 h21 (residual error,
39.4%). Since the 95% confidence intervals for CL/F included
zero for this model, an exponential model was examined. The
exponential model with creatinine clearance as a covariate of
lamivudine clearance was the final (superior) model (D 5
234.6).
Overall, the results of this study indicate that population
estimates for key lamivudine pharmacokinetic parameters, as
derived by NONMEM analysis, are consistent with values re-
ported in earlier, small-scale, phase I pharmacokinetic studies
employing traditional, intensive, serial blood sampling (10, 11,
13, 14, 16, 17, 19, 21). According to the final model, population
estimates for lamivudine CL/F (25.1 liters/h) and V/F (128
liters [1.8 liters/kg for a 70-kg person]) were within the ranges
observed by van Leeuwen et al. (19) and Yuen et al. (21) in
patients with asymptomatic HIV infection (CL/F 5 15.4 to 28
liters/h; V/F 5 1.0 to 2.2 liters/kg), assuming an absolute bio-
availability of 82%. A lamivudine ka has not been reported
previously in phase I pharmacokinetic studies. The large mag-
nitude of the population estimate for ka derived from the final
model (4.65 h21) was expected because lamivudine is known to
be absorbed rapidly, with a time to maximum serum drug
concentration of approximately 1 h (19, 21).
This is the first study to assess the population pharmacoki-
netics of lamivudine. Serum drug concentration data from
more patients (n 5 394) were evaluated in this study than in
comparable population pharmacokinetic studies of zidovudine
(72 patients) (6) and didanosine (69 patients) (15). The large
population allowed an exploration of possible relationships
between various covariates (gender, weight, race, age, renal
function, and surrogate markers of HIV disease) and lamivu-
dine pharmacokinetics that would not have been possible in a
traditional small-scale pharmacokinetic study.
The final model indicated that renal function was the most
significant covariate. This was not surprising, since Heald et al.
(10) and Johnson et al. (12) previously demonstrated a signif-
icant relationship between impaired renal function and lami-
vudine disposition after single-dose (300 mg) oral administra-
tion of lamivudine. Decreased renal lamivudine clearance, as is
evident in renally impaired patients, is associated with in-
creased lamivudine area under the concentration-time curve
and maximum concentration of drug in serum, and this neces-
sitates dosage modification according to creatinine clearance
(e.g., a 50% reduction in the daily lamivudine dose in patients
with creatinine clearances below 50 ml/min). The final model
in this population pharmacokinetic study similarly predicted
that the lamivudine area under the concentration-time curve
estimates following administration of a 150-mg dose increases
as renal impairment worsens. One limitation of our study was
that most of the patient population evaluated had normal renal
function; indeed, only three patients had an estimated creati-
nine clearance of ,60 ml/min. In view of this, the relationship
between creatinine clearance and lamivudine CL/F identified
in this population pharmacokinetic analysis should not be used
as a guide for dose modification.
Note that the population estimate of lamivudine CL/F was
not significantly influenced by weight-corrected gender and
race. In a previous study by Moore et al. (13), healthy female
subjects were found to have a lower lamivudine CL/F (liters
per hour) than male subjects but, as in the study presented
here, correction for weight eliminated any gender differences
in this parameter (measured in liters per hour per kilogram).
Age alone did not significantly affect either the lamivudine
CL/F or V/F. It should be kept in mind, though, that the age
range of the patients studied (19 to 64 years) may limit this
interpretation. The lack of influence of gender and age on drug
disposition in this study of lamivudine is comparable to that
reported in the population pharmacokinetic study of another
reverse transcriptase inhibitor, didanosine. Surrogate markers
of HIV disease (CD41 cell count, HIV-1 RNA PCR, and CDC
classification) did not influence lamivudine disposition. How-
ever, interpretation of these findings may be limited since only
12 patients had CD41 cell counts of ,100/mm3, indicating that
most of the patients were not severely immunosuppressed.
In conclusion, the results of this study indicated that popu-
lation estimates for lamivudine pharmacokinetic parameters
were generally in agreement with values derived from earlier,
small-scale, phase I pharmacokinetic studies. Lamivudine dis-
position was significantly influenced by renal function and was
not affected by weight-corrected gender and race. Lamivudine
dose adjustments in patients with renal impairment should be
based on information in the product label.
We thank the many clinical investigators, patients, and other people
who were associated with the NUCA3001 and NUCA3002 clinical
trials.
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